Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Index Can Predict Survival in Patients with MM

Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 19; Ely, et al

Plasma cell proliferation index (PCPI) can help predict overall survival in people with newly diagnosed multiple myeloma, according to a study involving 151 individuals. Furthermore, it enables broader use of multiple myeloma cell proliferation for categorizing risk. Investigators grouped participants based on low (n=87) and high (n=64) myeloma cell proliferation. Using a plasma cell-specific biomarker, they evaluated how well multiplex immunohistochemistry calculated a PCPI. Among the results:

  • Median overall survival was not reached in the low PCPI group, vs ~79 months in the high PCPI group.
  • Only high-risk cytogenetics, ISS stage >I, and PCPI >5 independently impacted overall survival.
  • 36% of patients with low risk disease were re-identified as high risk by PCPI.


Ely S, Forsberg P, Ouansafi I, et al. Cellular proliferation by multiplex immunohistochemistry identifies high risk multiple myeloma in newly diagnosed, treatment naïve patients. [Published online ahead of print September 19, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.010.

This Week's Must Reads

Apixaban surpasses DOACs in very elderly patients, Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900

Sickle cell: Daily hydroxyurea safe in African children, Tshilolo L et al. ASH 2018, Abstract 3

Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123

Similar VTE rates seen with tofacitinib, TNF inhibitors, Desai RJ et al. Arthritis Rheumatol. 2018;70(suppl 10), Abstract L09

Recurrence risk high regardless of VTE classification, Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4

Must Reads in Multiple Myeloma

Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123

RNA editing contributes to myeloma pathogenesis, Teoh PJ et al. Blood. 2018;132(12):1304-17

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.

Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894